|
G |
ALB |
albumin |
affects binding |
EXP |
chromotrope 2R binds to ALB protein |
CTD |
PMID:19347248 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
Benzenesulfonates analog inhibits the reaction [SLC10A1 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:22641618 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
|
G |
APP |
amyloid beta precursor protein |
multiple interactions affects binding |
ISO EXP |
Congo Red inhibits the reaction [APP protein binds to APP protein] Congo Red binds to APP protein |
CTD |
PMID:17323972 PMID:17406451 |
|
NCBI chr21:25,880,550...26,171,128
Ensembl chr21:25,880,535...26,171,128
|
|
G |
PRNP |
prion protein (Kanno blood group) |
decreases expression |
ISO |
Congo Red results in decreased expression of PRNP protein alternative form |
CTD |
PMID:11994310 |
|
NCBI chr20:4,686,456...4,701,588
Ensembl chr20:4,686,350...4,701,590
|
|
|
G |
IYD |
iodotyrosine deiodinase |
multiple interactions |
EXP |
Fast Green FCF inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions affects binding |
EXP ISO |
Indigo Carmine binds to and results in increased activity of AHR protein Indigo Carmine binds to AHR protein |
CTD |
PMID:11425848 PMID:15001395 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
CHRNA4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases activity increases expression multiple interactions |
EXP ISO |
Indigo Carmine results in increased activity of CYP1A1 protein Indigo Carmine results in increased expression of CYP1A1 mRNA Indigo Carmine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:15001395 PMID:15882963 PMID:18493746 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
GRIN2A |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,183,337
|
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
EXP |
Indocyanine Green inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Indocyanine Green results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
affects export |
ISO |
ABCB4 protein affects the export of Indocyanine Green |
CTD |
PMID:11302927 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Indocyanine Green results in increased expression of BAX mRNA; Indocyanine Green results in increased expression of BAX protein |
CTD |
PMID:23675521 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
CASP9 |
caspase 9 |
increases expression |
EXP |
Indocyanine Green results in increased expression of CASP9 mRNA; Indocyanine Green results in increased expression of CASP9 protein |
CTD |
PMID:23675521 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
multiple interactions increases uptake |
EXP |
Nifedipine promotes the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green]; Taurocholic Acid inhibits the reaction [SLC10A1 protein results in increased uptake of Indocyanine Green] |
CTD |
PMID:32209977 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC10A2 |
solute carrier family 10 member 2 |
increases uptake |
EXP |
SLC10A2 protein results in increased uptake of Indocyanine Green |
CTD |
PMID:32209977 |
|
NCBI chr13:103,043,998...103,066,417
Ensembl chr13:103,043,998...103,066,417
|
|
G |
SLC16A2 |
solute carrier family 16 member 2 |
multiple interactions |
EXP |
Indocyanine Green inhibits the reaction [SLC16A2 protein results in increased uptake of Triiodothyronine] |
CTD |
PMID:28119167 |
|
NCBI chr X:74,421,493...74,533,916
Ensembl chr X:74,421,493...74,533,917
|
|
G |
SLC22A7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
Indocyanine Green inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 |
|
NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
multiple interactions |
ISO |
Indocyanine Green inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:10224140 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions increases uptake increases transport |
EXP |
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Novobiocin inhibits the reaction [ABCG2 protein results in increased uptake of lucifer yellow]; Omeprazole inhibits the reaction [ABCG2 protein results in increased transport of lucifer yellow] |
CTD |
PMID:31348918 PMID:32305507 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
|
G |
CRH |
corticotropin releasing hormone |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [Lipopolysaccharides results in increased secretion of CRH protein]; Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 8:66,176,376...66,178,464
Ensembl chr 8:66,176,376...66,178,464
|
|
G |
EGFR |
epidermal growth factor receptor |
multiple interactions |
ISO |
Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of EGFR protein] |
CTD |
PMID:15309881 |
|
NCBI chr 7:55,019,017...55,211,628
Ensembl chr 7:55,019,017...55,211,628
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL1B protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [IL6 protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP ISO |
Dipyrone analog results in decreased activity of PTGS1 protein; Dipyrone results in decreased activity of PTGS1 protein |
CTD |
PMID:12242329 PMID:16141368 |
|
NCBI chr 9:122,370,533...122,395,703
Ensembl chr 9:122,370,530...122,395,703
|
|
G |
TGFA |
transforming growth factor alpha |
multiple interactions |
ISO |
Dipyrone promotes the reaction [Hydrochloric Acid results in increased expression of TGFA protein] |
CTD |
PMID:15309881 |
|
NCBI chr 2:70,447,284...70,553,826
Ensembl chr 2:70,447,284...70,554,193
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
Dipyrone inhibits the reaction [TNF protein results in increased secretion of CRH protein] |
CTD |
PMID:11852909 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
|
G |
IYD |
iodotyrosine deiodinase |
multiple interactions |
EXP |
Direct Red 81 inhibits the reaction [IYD protein results in increased metabolism of Monoiodotyrosine] |
CTD |
PMID:33352258 |
|
NCBI chr 6:150,369,012...150,405,969
Ensembl chr 6:150,368,892...150,405,969
|
|
|
G |
IL17A |
interleukin 17A |
increases expression |
ISO |
Sodium taurocholate increases expression of Il17a mRNA and protein in the pancreas |
RGD |
PMID:22990529 |
RGD:9068935 |
NCBI chr 6:52,186,375...52,190,638
Ensembl chr 6:52,186,375...52,190,638
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 (ABCC1 blood group) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCC4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:95,019,835...95,301,451
Ensembl chr13:95,019,835...95,301,475
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ADGRG1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
|
|
G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
|
|
G |
ADH4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,123,658...99,144,297
Ensembl chr 4:99,123,657...99,157,792
|
|
G |
ADH6 |
alcohol dehydrogenase 6 (class V) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,202,639...99,219,246
Ensembl chr 4:99,202,638...99,219,537
|
|
G |
AKR1C4 |
aldo-keto reductase family 1 member C4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1C4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949
|
|
G |
AKR1D1 |
aldo-keto reductase family 1 member D1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
|
|
G |
AKR7A2 |
aldo-keto reductase family 7 member A2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:19,302,708...19,312,146
Ensembl chr 1:19,301,991...19,312,144
|
|
G |
AKR7A3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770
|
|
G |
ALB |
albumin |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
AMPD3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:10,450,388...10,507,579
Ensembl chr11:10,308,313...10,507,579
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
|
|
G |
ATP8B1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
|
|
G |
BAAT |
bile acid-CoA:amino acid N-acyltransferase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400
|
|
G |
BACH1 |
BTB domain and CNC homolog 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr21:29,298,922...29,361,894
Ensembl chr21:29,194,071...29,630,751
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
CASP9 |
caspase 9 |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] affects the expression of CASP9 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CAT |
catalase |
decreases activity multiple interactions |
ISO EXP |
Tartrazine results in decreased activity of CAT protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA |
CTD |
PMID:20678534 PMID:33819548 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CHRNA4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of CHRNA4 protein |
CTD |
PMID:23429044 |
|
NCBI chr20:63,343,223...63,361,349
Ensembl chr20:63,343,223...63,378,401
|
|
G |
CHRNB2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of CHRNB2 protein |
CTD |
PMID:23429044 |
|
NCBI chr 1:154,567,778...154,580,013
Ensembl chr 1:154,567,778...154,580,013
|
|
G |
CSF1 |
colony stimulating factor 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CXCL8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
CYP7B1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DNAJB9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
|
|
G |
DNAJC10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464
|
|
G |
DNAJC18 |
DnaJ heat shock protein family (Hsp40) member C18 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:139,410,203...139,439,525
Ensembl chr 5:139,408,588...139,444,491
|
|
G |
DNAJC9 |
DnaJ heat shock protein family (Hsp40) member C9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:73,232,272...73,247,255
Ensembl chr10:73,183,362...73,247,255
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
ESR1 |
estrogen receptor 1 |
increases activity multiple interactions |
EXP |
Tartrazine results in increased activity of ESR1 protein fulvestrant inhibits the reaction [Tartrazine results in increased activity of ESR1 protein] |
CTD |
PMID:22562034 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
FMO1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
|
|
G |
FTH1 |
ferritin heavy chain 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:61,964,285...61,967,634
Ensembl chr11:61,959,718...61,967,634
|
|
G |
GCLM |
glutamate-cysteine ligase modifier subunit |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:93,885,199...93,909,430
Ensembl chr 1:93,885,199...93,909,456
|
|
G |
GJB2 |
gap junction protein beta 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:20,187,470...20,192,938
Ensembl chr13:20,187,463...20,192,938
|
|
G |
GPRC5B |
G protein-coupled receptor class C group 5 member B |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:19,856,691...19,885,634
Ensembl chr16:19,856,691...19,886,167
|
|
G |
GRIN2A |
glutamate ionotropic receptor NMDA type subunit 2A |
multiple interactions |
ISO |
[ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in decreased expression of GRIN2A protein; [ponceau 4R co-treated with Allura Red AC Dye co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt co-treated with Tartrazine co-treated with Amaranth Dye co-treated with brilliant blue co-treated with Indigo Carmine] results in increased expression of GRIN2A protein |
CTD |
PMID:23429044 |
|
NCBI chr16:9,753,404...10,182,908
Ensembl chr16:9,753,404...10,183,337
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
GSTA3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:52,896,646...52,909,698
Ensembl chr 6:52,896,639...52,909,698
|
|
G |
GSTA4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:52,977,953...52,995,284
Ensembl chr 6:52,977,948...52,995,304
|
|
G |
GSTT1 |
glutathione S-transferase theta 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA |
CTD |
PMID:33819548 |
|
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] affects the expression of HAVCR1 mRNA |
CTD |
PMID:32981412 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,026,742...157,069,396
|
|
G |
HPX |
hemopexin |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:6,431,049...6,440,987
Ensembl chr11:6,431,049...6,442,617
|
|
G |
IFI16 |
interferon gamma inducible protein 16 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
|
|
G |
IFI27 |
interferon alpha inducible protein 27 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:94,105,894...94,116,690
Ensembl chr14:94,104,836...94,116,695
|
|
G |
IL1R1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:102,070,390...102,179,874
Ensembl chr 2:102,064,544...102,179,874
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
LIPC |
lipase C, hepatic type |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
LY96 |
lymphocyte antigen 96 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:73,991,392...74,099,857
Ensembl chr 8:73,991,392...74,029,079
|
|
G |
MAF |
MAF bZIP transcription factor |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:79,202,622...79,600,737
Ensembl chr16:79,585,843...79,600,737
|
|
G |
MAFF |
MAF bZIP transcription factor F |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
|
|
G |
MAP2K2 |
mitogen-activated protein kinase kinase 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:4,090,321...4,124,122
Ensembl chr19:4,090,321...4,124,122
|
|
G |
MAP2K6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
|
|
G |
MAP3K5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:136,557,046...136,793,091
Ensembl chr 6:136,557,046...136,793,097
|
|
G |
MAPKAPK3 |
MAPK activated protein kinase 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:50,611,520...50,649,291
Ensembl chr 3:50,611,520...50,649,291
|
|
G |
MGST1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:16,347,115...16,593,331
Ensembl chr12:16,347,142...16,609,259
|
|
G |
MLKL |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960
|
|
G |
MMUT |
methylmalonyl-CoA mutase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:49,430,360...49,463,253
Ensembl chr 6:49,430,360...49,463,253
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
PAH |
phenylalanine hydroxylase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:102,836,889...102,958,441
Ensembl chr12:102,836,889...102,958,410
|
|
G |
PIK3C2A |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:17,086,575...17,207,986
Ensembl chr11:17,077,730...17,207,986
|
|
G |
PIK3C2G |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:18,242,961...18,726,817
Ensembl chr12:18,242,961...18,648,416
|
|
G |
PIK3R3 |
phosphoinositide-3-kinase regulatory subunit 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:46,040,140...46,174,901
Ensembl chr 1:46,040,140...46,133,036
|
|
G |
PPP1R3C |
protein phosphatase 1 regulatory subunit 3C |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:91,628,442...91,633,071
Ensembl chr10:91,628,442...91,633,071
|
|
G |
PRKD3 |
protein kinase D3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:37,250,502...37,324,833
Ensembl chr 2:37,250,502...37,324,833
|
|
G |
RARA |
retinoic acid receptor alpha |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:40,309,180...40,357,643
Ensembl chr17:40,309,180...40,357,643
|
|
G |
RASD1 |
ras related dexamethasone induced 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:17,494,437...17,496,395
Ensembl chr17:17,494,437...17,496,395
|
|
G |
RDH16 |
retinol dehydrogenase 16 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:56,951,431...56,957,608
Ensembl chr12:56,951,431...56,959,374
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLCO1B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SORL1 |
sortilin related receptor 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:121,452,314...121,633,763
Ensembl chr11:121,452,314...121,633,763
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SULT2A1 |
sulfotransferase family 2A member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
|
|
G |
TFF1 |
trefoil factor 1 |
multiple interactions increases expression |
EXP |
fulvestrant inhibits the reaction [Tartrazine results in increased expression of TFF1 mRNA] |
CTD |
PMID:22562034 |
|
NCBI chr21:42,362,282...42,366,535
Ensembl chr21:42,362,282...42,366,535
|
|
G |
TLR3 |
toll like receptor 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:186,069,156...186,088,073
Ensembl chr 4:186,068,911...186,088,073
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
[Tartrazine co-treated with Erythrosine] results in increased expression of TNF mRNA |
CTD |
PMID:32981412 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF9 |
TNF receptor superfamily member 9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:7,915,871...7,940,839
Ensembl chr 1:7,915,871...7,943,165
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
UGT2B4 |
UDP glucuronosyltransferase family 2 member B4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of UGT2B4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
|
|